Genetron: Up as test HCCscreen selected for public health use

Genetron Holdings

27/11/2020 15:32

** U.S.-listed shares of Chinese medtech firm Genetron
Holdings  GTH.O  gain ~2% to $13.50 
    ** GTH says HCCscreen was selected by National Cancer Center
and Wuxi municipal government for use in the "Liver Cancer Early
Screening Comprehensive Prevention and Control Project", a
public health initiative  urn:newsml:reuters.com:*:nBw8Hzf2va
    ** Co's blood-based next-generation sequencing test,
HCCscreen, is used for early detection of liver cancer in people
at high-risk due to chronic hepatitis B virus (HBV) infection
and/or liver cirrhosis  urn:newsml:reuters.com:*:nL4N2GR3Q2
    ** Co formed new operating center through joint venture
agreement with Wuxi, in which the parties will closely
collaborate- GTH
    ** Expects commercialization and revenue of HCCscreen to
accelerate in China 


 (Reporting by Shreyasee Raj in Bengaluru)
 ((Shreyasee.Raj@thomsonreuters.com;))